Kidney disease is one of the most common medical causes of a low red blood cell count, and the connection is direct: your kidneys produce the hormone that tells your bone marrow to make red blood cells in the first place. When kidney function declines, that hormonal signal weakens, and red blood cell production drops. But the story is more layered than a single missing hormone, involving iron metabolism, shortened cell lifespans, and chronic inflammation that compound the problem as kidney disease progresses.
Why Your Kidneys Control Red Blood Cell Production
Most people think of the kidneys as filters for waste and excess fluid, which they are. But the kidneys also serve as the body’s primary factory for erythropoietin, commonly called EPO. This hormone circulates to the bone marrow and stimulates the production of new red blood cells. Specifically, EPO is made by specialized cells nestled in the tissue surrounding the kidney’s tiny tubules, called peritubular cells or pericytes.1PubMed Central. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney The system is elegantly self-regulating: when oxygen levels in the blood drop, a molecular sensor called HIF-2 ramps up EPO production to compensate.2PubMed Central. Anaemia in kidney disease: harnessing hypoxia responses for therapy
In chronic kidney disease (CKD), this system breaks down. As the kidney tissue becomes scarred and fibrotic, those EPO-producing pericytes transform into myofibroblasts, cells that participate in scarring rather than hormone production. The result is a kidney that progressively loses its ability to manufacture EPO.3PubMed. Physiology and pathophysiology of renal erythropoietin-producing cells Without adequate EPO signaling, the bone marrow simply does not receive the message to produce enough red blood cells, and hemoglobin levels drift downward.
Iron Gets Locked Away
Low EPO is the headline cause of anemia in kidney disease, but it is not the whole story. Even when patients receive synthetic EPO to replace what the kidneys no longer make, many remain anemic. A major reason is that CKD disrupts iron metabolism in a way that starves the bone marrow of the raw material it needs to build hemoglobin.
The key player here is a small protein called hepcidin, which acts as a gatekeeper for iron in the body. Hepcidin blocks the absorption of iron from food in the gut and traps existing iron inside storage cells so it cannot be used for making red blood cells. In healthy people, hepcidin levels rise and fall to keep iron in balance. In CKD, two things go wrong at once: chronic inflammation drives hepcidin levels up, and the kidneys lose the ability to clear hepcidin efficiently. The combined effect is persistently high hepcidin, which locks iron away even when the body’s total iron stores are adequate.4PubMed Central. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease Patients with CKD who also have elevated inflammation markers show particularly high hepcidin levels, compounding the iron restriction.5PLOS ONE. The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease
This creates a frustrating clinical scenario sometimes called “functional iron deficiency.” Blood tests may show normal or even elevated ferritin levels (a marker of stored iron), but that iron is effectively locked in macrophages and unavailable for red blood cell production.6PubMed Central. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease Standard blood work can be misleading for this reason, and distinguishing true iron deficiency from the inflammatory trapping of iron sometimes requires additional markers beyond ferritin alone.7BIRDEM Medical Journal. Serum Soluble Transferrin Receptor-Ferritin Indices in Diagnosing and Differentiating Iron Deficiency Anemia from Anemia of Chronic Disease among Patients with Chronic Kidney Disease
Red Blood Cells That Die Too Soon
On top of producing fewer red blood cells, kidney disease shortens the lifespan of the ones that do get made. A normal red blood cell circulates for about 120 days before being recycled by the spleen. In people with CKD, uremic toxins, oxidative stress, and inflammatory molecules accelerate a process of premature red blood cell death, cutting their lifespan to roughly 60 to 90 days.8PubMed Central. Eryptosis in renal anemia: mechanisms, clinical implications, and therapeutic targeting Researchers have even confirmed under high-resolution imaging that red blood cells in uremic patients develop characteristic spiky surface deformities, rather than maintaining their smooth, disc-like shape.
This shortened survival means the bone marrow has to work harder just to maintain the same number of circulating red blood cells. When you combine reduced production (from low EPO), restricted iron supply (from high hepcidin), and faster destruction, you get a triple hit that explains why anemia in CKD is so persistent and difficult to fully correct.
How Anemia Tracks With Kidney Function
Anemia in kidney disease is not all-or-nothing. It tends to creep in gradually and worsen in step with declining kidney function. A U.S. study using nationally representative data found that about 15% of people with CKD had anemia overall, but the rate climbed steeply across disease stages: roughly 8% at stage 1, rising to over 53% at stage 5.9PubMed Central. Prevalence of Anemia in Chronic Kidney Disease in the United States A separate analysis focused on more advanced stages found severe anemia in about 18% of stage 3a patients, about 25% of stage 3b, roughly 41% of stage 4, and nearly 73% of stage 5.10Clinical Kidney Journal. Contemporary outcomes of anemia in US patients with chronic kidney disease
Hemoglobin levels correlate closely with the glomerular filtration rate, the standard measure of how well the kidneys are filtering. One study found a strong positive correlation between the two, meaning that as kidney filtration drops, hemoglobin reliably drops with it. That same study observed that the stage of filtration loss, rather than the degree of protein leakage in the urine, was the main driver of falling hemoglobin.11Kidney International Reports. GFR is a Key Determinant of Red Blood Cell Survival in Anemia Associated With Progressive CKD For people with early-stage CKD who feel fine, this means anemia can develop silently well before other obvious symptoms appear.
Why People With Diabetes Get Hit Earlier
If you have diabetes-related kidney disease, anemia tends to show up sooner and hit harder than it does in non-diabetic kidney disease at the same level of kidney function. One study comparing patients with diabetic nephropathy to those with kidney disease from other causes found that nearly half of the diabetic patients were anemic, while none of the non-diabetic patients with similar kidney function levels were.12PubMed. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy A larger project confirmed this pattern, reporting that anemia prevalence among diabetics was roughly two to ten times higher than in non-diabetics at comparable levels of kidney impairment.13European Cardiovascular Disease. Anaemia in Patients with Diabetic Nephropathy – Prevalence, Causes and Clinical Consequences
The reasons are not entirely settled, but diabetes damages small blood vessels in the kidney in distinctive ways that seem to impair EPO production disproportionately. The chronic inflammation and autonomic nerve damage associated with diabetes may also contribute. Practically, this means that if you have diabetes and even mild kidney impairment, anemia screening is worth discussing with your doctor earlier than guidelines for non-diabetic CKD might suggest.
What This Does to the Heart
Anemia from kidney disease is not just about feeling tired. It puts real strain on the cardiovascular system. When hemoglobin drops, the heart has to pump harder and faster to deliver enough oxygen to the body. Over time, this extra workload causes the heart muscle to thicken, particularly the left ventricle, a condition called left ventricular hypertrophy. That thickening is a major risk factor for heart failure, arrhythmias, and cardiovascular death in CKD patients.14PubMed. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease
This creates a vicious feedback loop: kidney disease causes anemia, anemia damages the heart, and heart damage further impairs kidney function. Cardiologists and nephrologists sometimes call this the “cardio-renal anemia syndrome,” and it is one of the reasons anemia management in CKD is treated as more than a quality-of-life issue.
Interestingly, while the heart effects of kidney-related anemia are well established, the cognitive effects are less clear-cut. A study following over 700 CKD patients for nearly three years found that anemia was not independently associated with cognitive decline after accounting for other clinical factors. About 46% of participants in the study had anemia, but their performance on cognitive tests did not differ from non-anemic participants over the follow-up period. So while fatigue and brain fog are real symptoms people experience, the fear that kidney-related anemia causes lasting cognitive damage does not appear to be supported by the available evidence.
Treating the Anemia
The approach to treating anemia in CKD typically involves two main strategies used together: replacing the missing EPO signal and replenishing iron stores.
Synthetic versions of EPO, called erythropoiesis-stimulating agents (ESAs), have been the backbone of treatment for over two decades. These injectable drugs mimic the hormone that the damaged kidneys can no longer produce adequately, stimulating the bone marrow to ramp up red blood cell production. ESAs are effective for most patients, but they come with an important caveat: pushing hemoglobin levels too high with ESAs has been linked to worse outcomes, including higher rates of cardiovascular events and death.15PubMed. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications For this reason, treatment guidelines generally recommend using ESAs to partially correct anemia rather than trying to normalize hemoglobin entirely.
Iron therapy works alongside ESAs to ensure the bone marrow has enough raw material. Here, the route of delivery matters significantly. A Cochrane review comparing intravenous (IV) iron to oral iron pills across dozens of studies found that IV iron was substantially more effective: patients receiving IV iron were roughly 70% more likely to reach their target hemoglobin, and their hemoglobin levels rose by an average of about 0.7 g/dL more than those on oral iron.16PubMed Central. Parenteral versus oral iron therapy for adults and children with chronic kidney disease Another meta-analysis found a similar advantage, particularly pronounced in dialysis patients, where IV iron led to a hemoglobin increase of about 0.8 g/dL more than oral iron.17PubMed. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis The advantage of IV iron makes sense given the hepcidin problem: when hepcidin is blocking iron absorption in the gut, swallowing iron pills is fighting an uphill battle.
When Standard Treatment Falls Short
A minority of CKD patients require unusually high ESA doses yet still struggle to maintain adequate hemoglobin. This resistance to EPO therapy is almost always driven by ongoing inflammation. Inflammatory molecules directly suppress the bone marrow’s ability to respond to EPO and simultaneously boost hepcidin production, further choking off iron availability.18PubMed. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation Identifying and treating the source of inflammation, whether it is an infection, poorly controlled autoimmune disease, or dialysis catheter-related issue, is often the most effective way to improve the anemia response.
Vitamin D deficiency has also emerged as a contributing factor. Low vitamin D levels are extremely common in CKD patients, and research has found an association between vitamin D deficiency and both lower hemoglobin and poorer response to ESAs. Administering vitamin D supplements, whether the standard form or an activated version, has been associated with improvements in anemia and reduced ESA requirements in some studies.19PubMed. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation The mechanism likely involves vitamin D’s anti-inflammatory properties, which may help break the cycle of inflammation-driven EPO resistance.
Nutritional deficiencies beyond iron also deserve attention, especially in people on dialysis. The dialysis process itself washes out water-soluble vitamins, and the dietary restrictions that kidney patients follow can limit intake of folate and vitamin B12, both of which are needed for healthy red blood cell production.20PubMed Central. Vitamin B12 deficiency in dialysis patients: risk factors, diagnosis, complications, and treatment: A comprehensive review Correcting these deficiencies is a straightforward step that is sometimes overlooked when the focus is squarely on EPO and iron.
A Newer Class of Oral Drugs
In recent years, a new category of medications has arrived that tackles kidney-related anemia from a different angle. These drugs, called HIF-prolyl hydroxylase inhibitors (HIF-PHIs), work by mimicking the body’s natural response to low oxygen. Instead of injecting synthetic EPO from outside, they trick the body’s oxygen-sensing system into thinking oxygen levels are low, which stimulates the kidneys and liver to produce more of their own EPO.21PubMed Central. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
What makes HIF-PHIs particularly appealing is that they address multiple problems at once. Beyond boosting EPO, they lower hepcidin levels and improve iron availability, potentially reducing the need for IV iron infusions.22PubMed. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease One drug in this class, daprodustat, is taken as a pill rather than given by injection, which is a practical advantage for patients who are not yet on dialysis and would prefer to avoid regular infusions or injections. Clinical data has shown that daprodustat effectively raises hemoglobin, hematocrit, and red blood cell counts.23PubMed Central. The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review Several HIF-PHIs have been approved in various countries, though long-term cardiovascular safety data is still being accumulated and these drugs remain relatively new compared to the decades of experience clinicians have with ESAs.
Children With Kidney Disease Face the Same Problem
Anemia from CKD is not limited to adults. Children with chronic kidney disease develop anemia through the same mechanisms, and the consequences can be especially serious during growth and development. Anemia in children with CKD is closely linked to the development of left ventricular hypertrophy, which remains a leading cause of death in young patients with advanced kidney disease. The treatment approach mirrors adult management with ESAs and iron, though dosing and targets are adjusted for age and growth considerations. Because children are still developing, the fatigue and reduced exercise tolerance from anemia can have outsized effects on school performance, social participation, and overall quality of life.
Acute Kidney Injury and Red Blood Cell Counts
Most of the discussion about kidney disease and anemia centers on chronic kidney disease, which makes sense because the anemia develops gradually alongside the slow loss of kidney tissue. But acute kidney injury (AKI) can also affect red blood cells, though the mechanism is different. In AKI, the problem is not usually a shortage of EPO but rather direct damage to red blood cells or the consequences of the underlying illness that triggered the kidney failure. For instance, conditions that cause destruction of red blood cells within the bloodstream, such as certain infections, transfusion reactions, or mechanical damage from artificial heart valves, can simultaneously overwhelm the kidneys with the debris from broken-down blood cells. Iron and hemoglobin deposits from this kind of destruction have been observed in kidney tissue, and the kidney damage in these settings can compound the anemia from the original blood cell destruction.
The distinction matters because treating anemia from AKI is primarily about treating the underlying cause and supporting the kidneys through recovery, not about long-term EPO replacement. Most people whose kidneys recover from an acute injury will see their red blood cell counts normalize on their own, unlike the sustained anemia of CKD that requires ongoing management.
Signs You Might Be Developing Kidney-Related Anemia
The symptoms of anemia from kidney disease overlap heavily with other common complaints, which is one reason it often goes unrecognized in early-stage CKD. Fatigue is the hallmark, but the kind of fatigue people describe is not just sleepiness. It is a deep, physical exhaustion that does not improve much with rest. Other common symptoms include:
- Pale skin: reduced hemoglobin means less red pigment in the blood, which shows in the skin, nail beds, and inner eyelids.
- Shortness of breath: especially with activity that used to feel easy, because the blood is carrying less oxygen.
- Dizziness or lightheadedness: from lower oxygen delivery to the brain, especially when standing up quickly.
- Cold intolerance: the body has a harder time regulating temperature when oxygen delivery is compromised.
- Difficulty concentrating: though as noted earlier, the evidence for long-lasting cognitive effects is limited.
Because these symptoms develop gradually and can be attributed to many other things, a routine blood count is often the first indication of trouble. If you have known kidney disease, regular monitoring of hemoglobin along with iron studies, ferritin, and transferrin saturation gives a more complete picture than hemoglobin alone. The misleading ferritin readings in the context of inflammation make it especially important not to rely on a single test to judge iron status.